Arena Pharmaceuticals Climbs on Me-Too Autoimmune Drug
Insights - Arena Pharmaceuticals (ARNA) was up as much as 40% on Wednesday with the release of phase I data for APD334.
Read NowInsights
Kite Pharma Inks Deal with Amgen in Move Towards ‘Platform’ Model
Insights - Shortly before the bell on Monday morning, Kite Pharma (KITE) announced an immunotherapy collaboration and licensing agreement with one of biotech’s juggernauts, Amgen (AMGN), to advance … Continue Reading
Read Now
2014 was Stellar for Biotech. Here’s to an Even Better 2015
Insights - 2014 was a stellar year in biotech, for investors as well as patients. Here’s to an even better 2015. Happy new year! At PropThink, our goal has always … Continue Reading
Read Now
Agenus Climbs on Royalty Potential from Pharma’s New Vaccine
Insights - Agenus (AGEN) announced on Thursday that a shingles vaccine being developed by GlaxoSmithKline (GSK), and using a proprietary adjuvant licensed from AGEN, was succesful in … Continue Reading
Read Now
Sorrento’s New Investor Isn’t JUST a Billionaire
Insights - Investor/entrepreneur Dr. Patrick Soon-Shiong is making a sizable investment in Sorrento Therapeutics (SRNE), in addition to forming a joint venture with the small company to develop … Continue Reading
Read Now
Puma Biotech’s Delay Increases Headline Risk in 2016
Insights - Puma Biotech (PBYI) on Tuesday evening announced a significant, unexpected delay in its timeline for filing a New Drug Application with the FDA for lead … Continue Reading
Read Now
Small Drug Companies Get Love on Avanir Buyout
Insights - Japanese drugmaker Otsuka Pharmaceutical Co. is buying US-based Avanir Pharmaceuticals (AVNR) for $3.5 billion, or $17/share, in a deal announced Tuesday morning. Despite a tremendous run … Continue Reading
Read Now